Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., O'Connor, T. E., Jeyakumar, N., Muhsen, I. N., Valtis, Y., Ahmed, N., Zhang, A., Miller, K., Dykes, K. C., Ahmed, M., Chen, E. C., Mercadal, S., Schwartz, M., Tracy, S. I., Dholaria, B., Mukherjee, A., Battiwalla, M., Logan, A. C., Ladha, A., Guzowski, C., Hoeg, R. T., Hilal, T., Moore, J., Connor, M. P., Hill, L. C., Tsai, S. B., Sasine, J. P., Solh, M. M., Kota, V. K., Koura, D., Veeraputhiran, M., Leonard, J. T., Frey, N. V., Park, J. H., Luskin, M. R., Bachanova, V., Galal, A., Pullarkat, V., Stock, W., Cassaday, R. D., Shah, B. D., Faramand, R., Muffly, L., Oliai, C., Yaghmour, G., Sutherland, K., Zambrano, H., Bradshaw, D., Kubiak, M., Majhail, N., Mountjoy, L., Malik, S. A., Mathews, J., Shaughnessy, P., Advani, A. S., Stefan, M., O'Dwyer, K. M., Lee, C. J., Blunk, B., Bishop, M. R. (2025). Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00321